Phase III results for 20vPnC vaccine for pneumococcal disease.- Pfizer
Related news and insights
Merck Inc.,announced V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, met its primary immunogenicity and safety endpoints in two trials of the V114 Phase III pediatric clinical program.
Pfizer announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for 20vPnC, the 20-valent pneumococcal conjugate vaccine candidate, as submitted for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older.
Merck has announced the company has submitted applications to the FDA and European Medicines Agency (EMA) for licensure of V 114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for use in adults 18 years of age and older for prevention of pneumococcal disease.